OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)

BIOGRAPHICAL SKETCH

NAME: Mathew L. Thakur

eRA COMMONS USER NAME: mlt101

POSITION TITLE: Professor of Radiology, Radiation Oncology and Urology

EDUCATION/TRAINING:

Bombay University, Bombay, India, B.Sc. Chemistry (1957-1961)

University of London, London, England, M.Sc. Analytical Chemistry (1967-1969)

University of London, London, England, Ph.D. Radiochemistry (1969-1973)

A. Personal Statement

I am a professor of Radiology and Radiation Oncology at Thomas Jefferson University in Philadelphia, PA. I am also the Director of the laboratories of Radiopharmaceutical research and Molecular Imaging. I obtained my MS and PhD degrees from the University London, England. The major thrust of my research is to develop radiopharmaceuticals for diagnostic and therapeutic applications. I have published more than 500 original articles, review papers, book chapters, abstracts, and editorials. I have also published four books and translated my basic research into clinical applications. I have given numerous invited presentations at home, abroad, in academic institutions, industries, and at national and international scientific gatherings. I hold 20 granted patents and serve on the editorial board for 14 journals. As a PI and Co-PI, my research has always been funded by federal, foundational, and industrial grants. Currently I hold three INDs from the US FDA to perform clinical research. My contributions to the field of nuclear medicine and molecular imaging are well recognized by my peers, for which I have received 10 national and International awards, including the Society of Nuclear Medicine’s highest honor, the Benedict Cassen award. I have been elected as President of three international societies, including the Society of Nuclear Medicine and Molecular Imaging.

My research starts from a hypothesis for which I choose or design a biomolecule that may be specific for a particular target. Such molecules consist of small compounds, antibodies, peptides, and PNAs. I then label a biomolecule with a suitable radionuclide for planar, SPECT or PET imaging, or for theranostic applications. I then evaluate the novel molecules ex vivo, in preclinical animal models, and then translate it into humans for a feasibility study before the labeled molecule is licensed to a commercial company for large scale clinical evaluation and eventual commercialization. I have been fortunate to have had four of my compounds commercialized and preparations are under way for two more to be taken into clinical trials.

To target VPAC, I designed, synthesized and evaluated Cu-64-TP3805 and translated its applications in early and accurate imaging breast, prostate and bladder cancer in humans. The results form the basis of this application that now conjugating Cu-67, a radionuclide of therapeutic importance, instead of Cu-64, a positron emitting sister radionuclide, will serve as an effective theranostic agent. We have the facilities and expertise to execute this project successfully.

Positions and Honors

Professional Positions

1961-1967 Scientific Assistant, Grade "B", Isotope Division, Bhabha Atomic Research Center, Trombay, Bombay, India

1967-1977 Scientific Staff, Grade I (Permanent Appointment), Medical Research Council, Cyclotron Unit, Hammersmith Hospital, London, England

1975-1976 Visiting Professor, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis MO

1977-1982 Associate Professor of Diagnostic Radiology, Yale University School of Medicine, New Haven CT

1977-1983 Research Associate, Chemistry Department, Brookhaven National Laboratory, Washington University School of Medicine, St. Louis, MO

1982-1994 Professor and Director of Radiopharmaceutical Research, TJU

1982-present Director of Laboratories of Radiopharmaceutical Research, Molecular Imaging and Bio-Fluid Diagnostics, Professor Radiation and Radiation Oncology, TJU

1991-present Professor of Radiation Oncology and Urology, TJU

1995-present Director of Nuclear Medicine Research and Laboratories of Radiopharmaceutical Research and Molecular Imaging, Member, Kimmel Cancer Center, TJU

2015-present Professor of Urology, TJU

Other Experience and Professional Memberships

1977-present Grant reviewer for DOE, VA, NIH, University of Kuwait, National Cancer Institute of Canada

1977-present International Expert: Radiochemistry and Radiopharmaceuticals; IAEA, Vienna, Austria

1977-present Member of the Scientific Program Committee for many international and national conferences

1977-present Member of 15 professional societies, reviewer for many scientific journals, invited speaker, national and international meetings and universities at home and abroad, consultant for radiopharmaceutical companies

1980-present Editor, four books

1982-1984 Director, NATO Advanced Study Institute

1982-present Member, Editorial Board, Nuclear Medicine Communications

1987-present Chairman, Scientific Advisory Committee, RhoMed/Palatin Technologies 1989-present: Member, Editorial Board, Nuclear Medicine and Biology

1989-1992 President, International Society of Radiolabeled Blood Elements

1990-2000 Member, Advisory Committee, USP

1991-1994 Member, NIH Study Section

1993-present Member, Editorial Board, Journal of Nuclear Medicine

1994-present Member, Editorial Board, Journal of the Indian Association of Clinical Medicine

1996-present Member, Editorial Board, European Journal of Nuclear Medicine

1997-2001 Delegate-at-Large, Society of Nuclear Medicine

1997-present Member, Editorial Board, Journal of Labeled Compounds and Radiopharmaceuticals

1999-present Associate Editor, Cancer Research

2001 Guest Editor, Seminars in Nuclear Medicine

2003 Vice President, Society of Nuclear Medicine

2004-2005 President, Society of Nuclear Medicine

2004-2009 Board of Directors, SNM

2006-2009 Chair, SNM Award Committee

2007-present Member of SNMMI Publication Committee

2013-present Vice President of National Academy of Inventors, Thomas Jefferson University Chapter

2015-present Member, Board of Directors, SNMMI Therapy Center of Excellence

Honors/Awards

1980 ACS Maurice Chamberland Award for "Contributions to the Improvement of the Quality of Life Through Chemistry"

1992 SNM Paul Aebersold Award for "Outstanding Achievement in Basic Science Applied to Nuclear Medicine"

1995 V. Sarabhai Oration Award for "Brilliant Accomplishments in the Field of Radiopharmaceuticals,” SNM, India

1998 Lifetime Achievement Award for “Outstanding Contributions to Nuclear Medicine,” IASNM

2000 G. de Hevesy Nuclear medicine Pioneer Award for “Outstanding Contributions to the Field of Nuclear Medicine"

2001 Berson-Yalow Award for “Outstanding Contributions to the Field of Nuclear Medicine,” SNM, Greater NY Chapter

2008 Benedict Cassen Award for “Outstanding Contribution to Radiopharmaceutical Science and Devotion to the Practice and Promotion of Nuclear Medicine,” SNM/ERF

2009 Siemen’s Medical Incorporation’s “Image of the Year" Award

2009 John McAfee medal for “Outstanding Achievements in the Field of Radiolabeled Blood Cells and his Meritorious Contributions to ISORBE,” Vienna, Austria

2015 Distinguished Investigator of the Academy of Radiology Research 2016: Fellow SNMMI (Society of Nuclear Medicine and Molecular Imaging)

2016 Honor of “Fellow” “indicating a prolific spirit of innovation in creating or facilitating inventions that have made a tangible impact on quality of life, economic development and the welfare of society,” SNMMI

2017 Honor of "Fellow," National Academy of Inventors

2018 Invited Keynote Speaker, The Black Graduate Student Organization 2nd Annual Diversity Graduate Research Symposium

2019 Ajit Padhy Award for outstanding contributions in Radiopharmaceutical sciences and developments, World Association of Radiopharmaceuticals and Molecular Therapy (WARMTH)

2021 Meet our Advisors: Mathew Thakur, J. Labelled Compounds and Radiopharmaceuticals, 1-4

2021 Albert Nelson Marquis Achievement Award for "having achieved Career Longevity and demonstrated unwavering excellence in his chosen field"

Contributions to Science

1. I designed and developed a 99mTc and 64Cu labeled peptide specific for genomic biomarker VPAC1 for imaging tumors. A generation of a large body of pre-clinical data in immunocompromised athymic nude mice and in transgenic mice, I translated the use of this biomolecule for imaging breast cancer in humans and in prostate cancer. A work is in progress for large scale clinical trials for commercialization of this molecule (⁶⁴Cu-TP3805).

• Tripathi SK, Trabulsi EJ, Gomella L, Kim S, McCue P, Intenzo CI, Gandhe A, Kumar P, and Thakur ML. VPAC1 Targeted Cu-64-TP3805 PET Imaging of Prostate Cancer: Preliminary Evaluation in Man. Urology. 2015;88:111-118. PMCID: PMC4788593

• Thakur ML, Zhang K, Berger A, Cavanaugh B, Kim S, Channappa C, Frangos AJ, Wickstrom E, Intenzo CM. VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study. J Nucl Med; 54:1019-1025, 2013. PMCID: PMC5506835

2. I have developed a peptide-fluorophore bio-conjugate to visualize cancer cells shed in voided urine of patients with urothelial cancer. This work is in progress.

• Trabulsi, E. J., Tripathi, S. K., Gomella, L., Solomides, C., Wickstrom, E. and Thakur, ML. (2017), Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study. BJU Int. doi:10.1111/bju.13775. PMCID: PMC5444967

A list of my bibliography can be found at http://www.ncbi.nlm.nih.gov/sites/myncbi/1-m4TAhF2c-kE/bibliography/45550866/public/?sort=date&direction=ascending. *This list may not contain all publications.

Additional Information: Research Support and/or Scholastic Performance

Ongoing:

NIH/NCI R01 CA249921-01 09/01/20 - 08/31/25

Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer

The major goal of this project is to develop a simple, affordable, noninvasive assay that will detect cancer by targeting VPAC receptors, shed in biofluids.

Role: PI

CHDI Foundation, Inc. 3/1/20 - 2/28/22

Huntingtin mRNA PET Imaging Therapeutic Efficacy

The major goal is to determine therapeutic efficacy by PET Imaging of Huntingtin mRNA

Role: Co-PI

KOP Therapeutics 11/01/2019 - 10/31/2024

Innovative Cancer Therapy Targeting a Novel Oncogene mRNA.

This investigation is designed to validate the hypothesis that a short RNA analogs will block a specific oncogene mRNA, resulting into malignant cellular stasis and reduce cell surface immune checkpoint proteins.

Role: PI

Completed:

·Jefferson’s KCC award 07/01/18 - 06/30/20

PET Imaging of Urothelial Bladder Cancer (Mathew Thakur, PI)

The goal of this investigation is to evaluate a feasibility of imaging urothelial bladder cancer in humans by targeting VPAC1 receptors.

Role: PI

NIH/NCI R01 CA157372 (Mathew Thakur, PI) 04/01/12 - 03/31/19 (NCE)

VPAC1 Receptor-Targeted PET Imaging of Prostate Cancer

The major goal of this project is preclinical development of gene product radioprobes for positron emission of tomography imaging of VPAC1 receptor expression

Role: PI